The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...

Not content with buying up a big chunk of the world’s generics market with its $40.5 billion merger with Actavis, Teva is muscling in on biosimilars with a deal with South Korea’s Celltrion.

The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain ...

Teva has agreed to pay a whopping $1.2 billion ... Other cases in the US include the FTC's pursuit of AbbVie subsidiary Solvay and Actavis unit Watson on testosterone replacement therapy product ...

Whereas Teva Pharmaceutical had north of $35 billion in net debt following its acquisition of Actavis in 2016, it now has less than $15.7 billion in net debt on its balance sheet. With Teva's long ...